SoDu-Based Chimerix Acquired in $935M Deal

The agreement, expected to close later this year, brings Chimerix’s promising brain cancer drug, dordaviprone, into Jazz’s growing oncology portfolio.

SoDu-Based Chimerix Acquired in $935M Deal